Αυγ312015Βιβλιογραφικά δεδομέναΓια να δείτε ολόκληρο το άρθρο πιέστε εδώ Κατηγορία Βιβλιογραφικά δεδομένα31 Αυγούστου 2015 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:14 Σεπτεμβρίου : Ημέρα για την Πρωτοπαθή Χολική ΚίρρωσηΕπόμενοNext post:EASL Clinical Practice Guidelines: Autoimmune hepatitisΣχετικά ΆρθραSafety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program3 Μαρτίου 2026Early Prognostic Factors for Reduced Survival in Autoimmune Hepatitis: A Systematic Review With Meta-Analysis27 Φεβρουαρίου 2026Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation18 Φεβρουαρίου 2026Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis2 Φεβρουαρίου 2026Autoimmune liver diseases in Latin America: Current landscape and challenge29 Ιανουαρίου 2026Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)27 Ιανουαρίου 2026
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program3 Μαρτίου 2026
Early Prognostic Factors for Reduced Survival in Autoimmune Hepatitis: A Systematic Review With Meta-Analysis27 Φεβρουαρίου 2026
Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation18 Φεβρουαρίου 2026
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis2 Φεβρουαρίου 2026
Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)27 Ιανουαρίου 2026
